Evidence map›Paper›PMID 40822466›Full record

ArticleFrontiers in pharmacology2025

Dihydroartemisinin decreases pre-existing neutralizing antibodies against adeno-associated virus in challenged mice.

Jingjing Fang, Enze Cui, Jinyan Xie, Xuxia Gao, Yun He, Ming Yang, Sana Shaheen, Zhengjun Zhou, Shaolai Zhou, Binbin Cheng and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jingjing Fang *Oncology Department of Traditional Chinese Medicine, Changhai Hospital, Naval Medical University, Shanghai, China.
Enze Cui *Oncology Department of Traditional Chinese Medicine, Changhai Hospital, Naval Medical University, Shanghai, China.
Jinyan XieState Key Laboratory of Genetics and Development of Complex Phenotypes and Engineering Research Center of Gene Technology (Ministry of Education), School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.
Xuxia GaoState Key Laboratory of Genetics and Development of Complex Phenotypes and Engineering Research Center of Gene Technology (Ministry of Education), School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.
Yun HeState Key Laboratory of Genetics and Development of Complex Phenotypes and Engineering Research Center of Gene Technology (Ministry of Education), School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.
Ming YangState Key Laboratory of Genetics and Development of Complex Phenotypes and Engineering Research Center of Gene Technology (Ministry of Education), School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.
Sana ShaheenState Key Laboratory of Genetics and Development of Complex Phenotypes and Engineering Research Center of Gene Technology (Ministry of Education), School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhengjun ZhouDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Shaolai ZhouDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Binbin ChengOncology Department of Traditional Chinese Medicine, Changhai Hospital, Naval Medical University, Shanghai, China.
Changquan LingOncology Department of Traditional Chinese Medicine, Changhai Hospital, Naval Medical University, Shanghai, China.
Chen LingState Key Laboratory of Genetics and Development of Complex Phenotypes and Engineering Research Center of Gene Technology (Ministry of Education), School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The high prevalence of pre-existing neutralizing antibodies (NAbs) against adeno-associated virus (AAV) poses a major obstacle to in vivo gene therapy. Current immunosuppressive (IS) strategies, such as corticosteroids, are limited by toxicity and adverse effects. To explore safer alternatives, we evaluated dihydroartemisinin (DHA), a synthetic derivative of artemisinin inspired by traditional Chinese medicine (TCM), as a potential IS agent. Methods: In vivo experiments were conducted by administering DHA at either 30 or 210 days post-injection (PI) of rAAVDJ vectors. Anti-AAV NAb levels, transgene expression, and vector genome biodistribution were assessed. Flow cytometry was used to quantify CD20 Results: DHA administration significantly reduced anti-AAV NAb levels without compromising transgene expression or vector genome distribution. DHA treatment resulted in a reduction of splenic CD20 Discussion: These findings suggest that DHA is a safe and effective agent for modulating humoral immune responses to AAV vectors. Our results provide proof-of-concept evidence supporting the use of TCM-derived compounds to address immunological barriers in gene therapy.

Indexed as

adeno-associated virus vectordihydroartemisiningene therapyimmunosuppression agentsneutralizing antibodytraditional Chinese medicine

Identifiers

PMID40822466
PMCPMC12355050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.